# Special Issue

# Current Status and Future Prospects of Histopathology in Cancer Diagnosis

## Message from the Guest Editors

In recent years, the field of histopathology has undergone several innovations, and tissue analysis has substantially contributed to improving the current knowledge on cancer pathophysiology. Indeed, advancements in the fields of cancer genomics and epigenomics have allowed for the identification of new tumor entities and the refinement of histological classifications. This Special Issue aims to highlight the most recent advances in the field of oncological histopathology and welcome original research articles and systematic reviews focused on cutting-edge discoveries in cancer diagnostics, with particular interest in studies that aim to identify correlations between tumor morphology and immunophenotypical and/or molecular features in human cancers. We also encourage fellow researchers to submit articles on new tissue biomarkers that may provide prognostic information and aid in selecting the most appropriate therapeutic strategies for patients with cancer.

### **Guest Editors**

### Dr. Serena Ammendola

Division of Pathology, Department of Diagnostics and Public Health, Azienda Ospedaliera Universitaria Integrata of Verona, 37134 Verona, Italy

#### Dr. Valeria Barresi

Department of Diagnostics and Public Health, P.le L.A. Scuro, University of Verona, 37129 Verona, Italy

### Deadline for manuscript submissions

31 October 2025



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 4.1
Indexed in PubMed



### mdpi.com/si/206157

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

<u>jpm</u>





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 4.1 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

### Editor-in-Chief

### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

### Journal Rank:

CiteScore - Q2 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.4 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2024).

